Organogenesis (ORGO) Stock Price, News & Analysis

Company Overview

Organogenesis Holdings Inc. (NASDAQ: ORGO) is a regenerative medicine company focused on the development, manufacture and commercialization of advanced tissue repair solutions. The company operates two principal business segments—Advanced Wound Care and Surgical Orthobiologics—offering a range of human cellular and tissue‐based products designed to support the body’s natural healing processes. Organogenesis’ therapies address chronic and acute wounds as well as a variety of surgical soft tissue repair needs.

In its Advanced Wound Care segment, Organogenesis markets living and non‐living skin substitutes and placental tissue products, including offerings that target diabetic foot ulcers, venous leg ulcers and other difficult‐to‐treat wounds. Within the Surgical Orthobiologics business, the company provides demineralized bone matrices, amniotic membrane grafts and other matrix products engineered to support tendon, ligament, nerve and soft tissue repair. These products are distributed primarily through a direct sales force across hospitals, wound care centers and specialty clinics in the United States, with select partnerships extending distribution into international markets.

Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has grown through internal innovation, strategic acquisitions and collaborative research agreements with leading academic and clinical institutions. The company maintains FDA‐registered manufacturing facilities in the U.S. and holds an extensive intellectual property portfolio covering its cell and tissue technologies. Over its history, Organogenesis has expanded its product pipeline and production capacity to meet evolving clinical needs.

Organogenesis is led by an executive management team and board of directors with deep expertise in biotechnology, medical devices and healthcare commercialization. Leadership priorities include scaling commercial operations, advancing clinical development programs and expanding global access to regenerative therapies. The company continues to invest in research and development to bolster its pipeline and drive sustainable long-term growth in the regenerative medicine market.

Key Stats

• Today's Range: $4.30 to $4.59
• 50-Day Range: $2.66 to $4.63
• 52-Week Range: $2.28 to $6.71
• Volume: 956,494 shs
• Average Volume: 1.14 million shs
• Market Capitalization: $578.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Moderate Buy

Organogenesis Stock Analysis - MarketRank™

Organogenesis scored higher than 90% of companies evaluated by MarketBeat, and ranked 103rd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Organogenesis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Organogenesis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Organogenesis are expected to grow in the coming year, from ($0.07) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organogenesis is -26.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organogenesis is -26.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Organogenesis has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.93% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Organogenesis has recently decreased by 5.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organogenesis does not currently pay a dividend.

Dividend Growth

Organogenesis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.01

Percentage of Shares Shorted

15.93% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Organogenesis has recently decreased by 5.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.06

News Sentiment

Organogenesis has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Organogenesis this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for ORGO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Organogenesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $725,732.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

33.00% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORGO Stock Analysis - Frequently Asked Questions

How have ORGO shares performed this year?

Organogenesis' stock was trading at $3.20 at the start of the year. Since then, ORGO shares have increased by 42.5% and is now trading at $4.56.

How were Organogenesis' earnings last quarter?

Organogenesis (NASDAQ:ORGO) posted its earnings results on Thursday, May, 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.17. The firm earned $86.69 million during the quarter, compared to analysts' expectations of $90.77 million. Organogenesis had a negative trailing twelve-month return on equity of 4.00% and a negative net margin of 3.46%.
Read the conference call transcript.

Who are Organogenesis' major shareholders?

Top institutional shareholders of Organogenesis include Assenagon Asset Management S.A. (2.25%), HighMark Wealth Management LLC (0.23%), Wealth Enhancement Advisory Services LLC (0.03%) and Pallas Capital Advisors LLC (0.02%). Insiders that own company stock include Albert Erani, Gary S Gillheeney, Lori Freedman, Michael Joseph Driscoll, Michael W Katz and Arthur S Leibowitz.
View institutional ownership trends.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organogenesis investors own include NVIDIA (NVDA), Financial Select Sector SPDR Fund (XLF), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Energy Transfer (ET), Moderna (MRNA) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORGO
• CIK: 1661181
• Web: organogenesis.com
• Phone: (781) 575-0775
• Fax: N/A
• Employees: 950
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Organogenesis: $6.50
• High Price Target: $7.00
• Low Price Target: $6.00
• Potential Upside/Downside: +42.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $860 thousand
• Net Margins: -3.46%
• Pretax Margin: -5.29%
• Return on Equity: -4.00%
• Return on Assets: -2.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.12
• Quick Ratio: 3.67

Sales & Book Value

• Annual Sales: $482.04 million
• Price / Sales: 1.20
• Cash Flow: $0.22 per share
• Price / Cash Flow: 20.94
• Book Value: $2.09 per share
• Price / Book: 2.18

Miscellaneous

• Outstanding Shares: 126,850,000
• Free Float: 84,992,000
• Market Cap: $578.44 million
• Optionable: Optionable
• Beta: 1.70